USV Launches Concordance Tool to Empower Gestational Diabetes Care in India

USV, an Indian multinational healthcare company and holds the #1 position by prescriptions in the Oral Anti-Diabetic and Cardiology markets, has introduced a first-of-its-kind Concordance Tool for Gestational Diabetes Mellitus (GDM).

This initiative aims to improve short-term pregnancy outcomes and support long-term health in women affected by GDM.

GDM affects up to 14% of pregnancies in India, with prevalence rising to nearly 18% in urban areas. Left unmanaged, it can result in serious complications for both mother and child, while significantly increasing the mother's risk of developing type 2 diabetes, cardiovascular disease, and certain cancers. These risks can also carry over to the next generation, fueling a cycle of chronic illness.

The Concordance Tool is a structured, visual aid designed for gynecologists, obstetricians, and expecting mothers—especially in high-volume clinical settings. It enables users to:

• Understand GDM and its risks
• Emphasize early screening and lifestyle interventions
• Support shared decision-making and treatment adherence
• Reinforce postpartum follow-up to prevent progression to type 2 diabetes

Research shows that 70–85% of GDM cases can be effectively managed through timely diagnosis, nutrition therapy, and weight management.

This tool represents a meaningful shift from reactive care to proactive prevention—ensuring healthier futures for both mothers and their children.

To request the Concordance Tool, please fill out the form here: https://forms.gle/XsZKexheCxwEm4nc9

About USV: Established in 1961, USV Private Limited is a leading Indian multinational healthcare company with a presence in 65+ countries. In India, USV holds the #1 position by prescriptions in the Oral Anti-Diabetic and Cardiology markets. Its global portfolio includes APIs, generics, branded generics, peptides, and biosimilars.

References:

• Vinoth N, Jaget N, Sekar SG, Priyanka R. A study on prevalence of gestational diabetes mellitus and its associated risk indicators in pregnant women attending antenatal clinic in a tertiary health centre. Int J Reprod Contracept Obstet Gynecol 2023;12:1374-8.
• Rasmussen L, Poulsen CW, Kampmann U, Smedegaard SB, Ovesen PG, Fuglsang J. Diet and Healthy Lifestyle in the Management of Gestational Diabetes Mellitus. Nutrients. 2020 Oct 6;12(10):3050. doi: 10.3390/nu12103050. PMID: 33036170; PMCID: PMC7599681.
• Wicklow B, Retnakaran R. Gestational Diabetes Mellitus and Its Implications across the Life Span. Diabetes Metab J. 2023 May;47(3):333-344. doi: 10.4093/dmj.2022.0348. Epub 2023 Feb 8. PMID: 36750271; PMCID: PMC10244196.